A New Anti-Aging Drug Looks to Turn Back the Clock on Skin Age

Rubedo Life Sciences is testing a topical drug that clears senescent skin cells by temporarily inhibiting GPX4 to make those “zombie” cells vulnerable to ferroptosis while preserving and reviving nearby stressed but non-senescent cells. In a small trial of 11 people with atopic dermatitis, four weeks of daily application lowered measured biological (epigenetic) skin age by about two years on average according to an independent methylation clock; one participant showed a reduction of more than 11 years. The treatment also reduced inflammation-related markers and increased a collagen subtype linked to elasticity by roughly 10 percent. In a separate 18-person trial for actinic keratosis the cream produced a 46 percent drop in total lesions after one month.

The company is expanding studies to psoriasis, sun-damaged skin and hereditary hair loss, and plans a lower-potency over-the-counter formulation to compete with retinol plus an oral version targeting metabolic aging. Researchers caution that epigenetic clocks measure methylation patterns rather than direct functional rejuvenation, and that senescent cells play beneficial roles in wound healing and tumor suppression. The results are novel and promising but early-stage; the outcomes that will determine value are visible, durable improvements in skin appearance and function and safety across broader, healthier populations.